Anders Carey K, Van Swearingen Amanda E D, Neman Josh, Joyce Johanna A, Cittelly Diana M, Valiente Manuel, Zimmer Alexandra S, Floyd Scott R, Dhakal Ajay, Sengupta Soma, Ahluwalia Manmeet S, Nagpal Seema, Kumthekar Priya U, Emerson Sam, Basho Reva, Beal Kathryn, Moss Nelson S, Razis Evangelia D, Yang Jonathan T, Sammons Sarah L, Sahebjam Solmaz, Tawbi Hussein A
Duke Center for Brain and Spine Metastasis, Duke Cancer Institute, Durham, North Carolina, USA.
University of Southern California, Los Angeles, California, USA.
Neurooncol Adv. 2025 Mar 4;7(1):vdaf049. doi: 10.1093/noajnl/vdaf049. eCollection 2025 Jan-Dec.
Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, the risk for central nervous system (CNS) recurrence has increased. Historically, patients with BrM were excluded from clinical trials; however, there has been a shift toward increasing inclusion over the past decade. To most effectively design the next generation of clinical trials for patients with BrM, a multidisciplinary team spanning local and systemic therapies is imperative. CIMARa (Consortium for Intracranial Metastasis Academic Research), formalized in June 2021, is an inclusive group of multidisciplinary clinical investigators, research scientists, and advocates who share the collective goal of improving outcomes for patients with BrM. CIMARa aims to improve outcomes through the development, coordination, and awareness of multi-institutional clinical trials testing novel therapeutic agents for this unique patient population alongside the translation of preclinical research to the clinical setting.
实体瘤引起的脑转移（BrM）是一个日益严重且往往具有毁灭性的临床挑战，每年在全球影响着数十万患者。随着全身抗癌治疗方法的改进以及患者生存期的延长，中枢神经系统（CNS）复发的风险也在增加。从历史上看，患有脑转移的患者被排除在临床试验之外；然而，在过去十年中，情况已转向越来越多地纳入此类患者。为了最有效地设计针对脑转移患者的下一代临床试验，组建一个涵盖局部和全身治疗的多学科团队势在必行。CIMARa（颅内转移学术研究联盟）于2021年6月正式成立，是一个由多学科临床研究人员、科研人员和倡导者组成的包容性团体，他们有着共同的目标，即改善脑转移患者的治疗效果。CIMARa旨在通过开展、协调和推广多机构临床试验来改善治疗效果，这些试验针对这一独特患者群体测试新型治疗药物，并将临床前研究成果转化到临床实践中。
